O	0	5	Basic	Basic	JJ	B-NP
O	6	16	fibroblast	fibroblast	NN	I-NP
O	17	23	growth	growth	NN	I-NP
O	24	30	factor	factor	NN	I-NP
O	30	31	:	:	:	O
O	32	33	a	a	DT	B-NP
O	34	41	missing	missing	JJ	I-NP
O	42	46	link	link	NN	I-NP
O	47	54	between	between	IN	B-PP
O	55	63	collagen	collagen	NN	B-NP
O	64	67	VII	VII	CD	I-NP
O	67	68	,	,	,	O
O	69	78	increased	increase	VBN	B-NP
O	79	90	collagenase	collagenase	NN	I-NP
O	90	91	,	,	,	O
O	92	95	and	and	CC	O
B-Cancer	96	104	squamous	squamous	JJ	B-NP
I-Cancer	105	109	cell	cell	NN	I-NP
I-Cancer	110	119	carcinoma	carcinoma	NN	I-NP
O	120	122	in	in	IN	B-PP
O	123	132	recessive	recessive	JJ	B-NP
O	133	143	dystrophic	dystrophic	JJ	I-NP
O	144	157	epidermolysis	epidermolysis	NN	I-NP
O	158	165	bullosa	bullosa	NN	I-NP
O	165	166	.	.	.	O

O	167	177	BACKGROUND	BACKGROUND	NN	B-NP
O	177	178	:	:	:	O
O	179	187	Patients	Patient	NNS	B-NP
O	188	192	with	with	IN	B-PP
O	193	202	recessive	recessive	JJ	B-NP
O	203	213	dystrophic	dystrophic	JJ	I-NP
O	214	227	epidermolysis	epidermolysis	NN	I-NP
O	228	235	bullosa	bullosa	NN	I-NP
O	236	237	(	(	(	O
O	237	241	RDEB	RDEB	NN	B-NP
O	241	242	)	)	)	O
O	243	247	have	have	VBP	B-VP
O	248	260	deficiencies	deficiency	NNS	B-NP
O	261	263	of	of	IN	B-PP
O	264	272	collagen	collagen	NN	B-NP
O	273	277	type	type	NN	I-NP
O	278	281	VII	VII	CD	I-NP
O	282	285	and	and	CC	O
O	286	290	have	have	VBP	B-VP
O	291	299	elevated	elevate	VBN	I-VP
O	300	306	levels	level	NNS	B-NP
O	307	309	of	of	IN	B-PP
O	310	320	fibroblast	fibroblast	NN	B-NP
O	321	332	collagenase	collagenase	NN	I-NP
O	332	333	,	,	,	O
O	334	337	and	and	CC	O
O	338	339	a	a	DT	B-NP
O	340	347	greatly	greatly	RB	I-NP
O	348	357	increased	increase	VBN	I-NP
O	358	362	risk	risk	NN	I-NP
O	363	365	of	of	IN	B-PP
B-Cancer	366	375	cutaneous	cutaneous	JJ	B-NP
I-Cancer	376	384	squamous	squamous	JJ	I-NP
I-Cancer	385	389	cell	cell	NN	I-NP
I-Cancer	390	399	carcinoma	carcinoma	NN	I-NP
O	399	400	.	.	.	O

O	401	409	Patients	Patient	NNS	B-NP
O	410	414	with	with	IN	B-PP
O	415	420	other	other	JJ	B-NP
O	421	428	genetic	genetic	JJ	I-NP
O	429	439	blistering	blistering	NN	I-NP
O	440	449	disorders	disorder	NNS	I-NP
O	450	452	do	do	VBP	B-VP
O	453	456	not	not	RB	I-VP
O	457	461	have	have	VB	I-VP
O	462	470	elevated	elevate	VBN	I-VP
O	471	482	collagenase	collagenase	NN	B-NP
O	483	485	or	or	CC	O
O	486	488	an	an	DT	B-NP
O	489	498	increased	increase	VBN	I-NP
O	499	503	risk	risk	NN	I-NP
O	504	506	of	of	IN	B-PP
B-Cancer	507	515	squamous	squamous	JJ	B-NP
I-Cancer	516	520	cell	cell	NN	I-NP
I-Cancer	521	530	carcinoma	carcinoma	NN	I-NP
O	530	531	,	,	,	O
O	532	539	despite	despite	IN	B-PP
O	540	547	chronic	chronic	JJ	B-NP
O	548	556	wounding	wounding	NN	I-NP
O	556	557	.	.	.	O

O	558	561	The	The	DT	B-NP
O	562	572	connection	connection	NN	I-NP
O	573	580	between	between	IN	B-PP
O	581	589	collagen	collagen	NN	B-NP
O	590	594	type	type	NN	I-NP
O	595	598	VII	VII	CD	I-NP
O	599	609	deficiency	deficiency	NN	I-NP
O	609	610	,	,	,	O
O	611	620	increased	increase	VBN	B-NP
O	621	632	collagenase	collagenase	NN	I-NP
O	632	633	,	,	,	O
O	634	637	and	and	CC	O
B-Cancer	638	646	squamous	squamous	JJ	B-NP
I-Cancer	647	651	cell	cell	NN	I-NP
I-Cancer	652	661	carcinoma	carcinoma	NN	I-NP
O	662	664	is	be	VBZ	B-VP
O	665	668	not	not	RB	I-VP
O	669	679	understood	understand	VBN	I-VP
O	679	680	.	.	.	O

O	681	690	MATERIALS	MATERIALS	NNS	B-NP
O	691	694	AND	AND	CC	I-NP
O	695	702	METHODS	METHODS	NNS	I-NP
O	702	703	:	:	:	O
B-Organism_substance	704	709	Urine	Urine	NN	B-NP
O	710	714	from	from	IN	B-PP
O	715	717	81	81	CD	B-NP
O	718	726	patients	patient	NNS	I-NP
O	727	731	with	with	IN	B-PP
O	732	736	RDEB	RDEB	NN	B-NP
O	737	738	(	(	(	O
O	738	740	39	39	CD	B-NP
O	741	749	patients	patient	NNS	I-NP
O	749	750	)	)	)	O
O	750	751	,	,	,	O
O	752	762	junctional	junctional	JJ	B-NP
O	763	776	epidermolysis	epidermolysis	NN	I-NP
O	777	784	bullosa	bullosa	NN	I-NP
O	785	786	(	(	(	O
O	786	789	JEB	JEB	NN	B-NP
O	789	790	;	;	:	O
O	791	793	12	12	CD	B-NP
O	794	802	patients	patient	NNS	I-NP
O	802	803	)	)	)	O
O	803	804	,	,	,	O
O	805	808	and	and	CC	O
O	809	822	epidermolysis	epidermolysis	NN	B-NP
O	823	830	bullosa	bullosa	NN	I-NP
O	831	838	simplex	simplex	NN	I-NP
O	839	840	(	(	(	O
O	840	843	EBS	EBS	NN	B-NP
O	843	844	;	;	:	O
O	845	847	30	30	CD	B-NP
O	848	856	patients	patient	NNS	I-NP
O	856	857	)	)	)	O
O	857	858	,	,	,	O
O	859	861	as	as	RB	B-CONJP
O	862	866	well	well	RB	I-CONJP
O	867	869	as	as	IN	I-CONJP
O	870	880	unaffected	unaffected	JJ	B-NP
O	881	887	family	family	NN	I-NP
O	888	895	members	member	NNS	I-NP
O	896	898	of	of	IN	B-PP
O	899	903	RDEB	RDEB	NN	B-NP
O	904	912	patients	patient	NNS	I-NP
O	913	914	(	(	(	O
O	914	916	33	33	CD	B-NP
O	917	925	patients	patient	NNS	I-NP
O	925	926	)	)	)	O
O	926	927	,	,	,	O
O	928	931	was	be	VBD	B-VP
O	932	938	tested	test	VBN	I-VP
O	939	942	for	for	IN	B-PP
O	943	946	the	the	DT	B-NP
O	947	955	presence	presence	NN	I-NP
O	956	958	of	of	IN	B-PP
O	959	964	basic	basic	JJ	B-NP
O	965	975	fibroblast	fibroblast	NN	I-NP
O	976	982	growth	growth	NN	I-NP
O	983	989	factor	factor	NN	I-NP
O	990	991	(	(	(	O
O	991	995	bFGF	bFGF	NN	B-NP
O	995	996	)	)	)	O
O	997	1002	using	use	VBG	B-VP
O	1003	1004	a	a	DT	B-NP
O	1005	1014	sensitive	sensitive	JJ	I-NP
O	1015	1031	radioimmunoassay	radioimmunoassay	NN	I-NP
O	1031	1032	.	.	.	O

O	1033	1038	These	These	DT	B-NP
O	1039	1047	patients	patient	NNS	I-NP
O	1048	1056	included	include	VBD	B-VP
O	1057	1061	many	many	JJ	B-NP
O	1062	1065	who	who	WP	B-NP
O	1066	1070	were	be	VBD	B-VP
O	1071	1079	enrolled	enrol	VBN	I-VP
O	1080	1082	in	in	IN	B-PP
O	1083	1086	the	the	DT	B-NP
O	1087	1100	Epidermolysis	Epidermolysis	NNP	I-NP
O	1101	1108	Bullosa	Bullosa	NNP	I-NP
O	1109	1117	Registry	Registry	NNP	I-NP
O	1118	1121	and	and	CC	O
O	1122	1128	others	other	NNS	B-NP
O	1129	1132	who	who	WP	B-NP
O	1133	1137	were	be	VBD	B-VP
O	1138	1146	referred	refer	VBN	I-VP
O	1147	1149	by	by	IN	B-PP
O	1150	1155	their	their	PRP$	B-NP
O	1156	1166	physicians	physician	NNS	I-NP
O	1166	1167	.	.	.	O

O	1168	1175	RESULTS	RESULTS	NNS	B-NP
O	1175	1176	:	:	:	O
O	1177	1182	Fifty	Fifty	CD	B-NP
O	1182	1183	-	-	HYPH	I-NP
O	1183	1186	one	one	CD	I-NP
O	1187	1194	percent	percent	NN	I-NP
O	1195	1197	of	of	IN	B-PP
O	1198	1206	patients	patient	NNS	B-NP
O	1207	1211	with	with	IN	B-PP
O	1212	1216	RDEB	RDEB	NN	B-NP
O	1217	1220	had	have	VBD	B-VP
O	1221	1229	elevated	elevate	VBN	I-VP
O	1230	1236	levels	level	NNS	B-NP
O	1237	1238	(	(	(	O
O	1239	1246	greater	great	JJR	B-NP
O	1247	1251	than	than	IN	I-NP
O	1253	1257	5000	5000	CD	I-NP
O	1258	1260	pg	pg	NN	I-NP
O	1260	1261	/	/	SYM	B-NP
O	1261	1262	g	g	NN	I-NP
O	1262	1263	)	)	)	O
O	1264	1266	of	of	IN	B-PP
B-Organism_substance	1267	1274	urinary	urinary	JJ	B-NP
O	1275	1279	bFGF	bFGF	NN	I-NP
O	1279	1280	.	.	.	O

O	1281	1283	In	In	IN	B-PP
O	1284	1292	contrast	contrast	NN	B-NP
O	1292	1293	,	,	,	O
O	1294	1298	none	none	NN	B-NP
O	1299	1301	of	of	IN	B-PP
O	1302	1305	the	the	DT	B-NP
O	1306	1314	patients	patient	NNS	I-NP
O	1315	1319	with	with	IN	B-PP
O	1320	1323	JEB	JEB	NN	B-NP
O	1324	1327	had	have	VBD	B-VP
O	1328	1336	elevated	elevate	VBN	I-VP
O	1337	1343	levels	level	NNS	B-NP
O	1344	1346	of	of	IN	B-PP
O	1347	1351	bFGF	bFGF	NN	B-NP
O	1351	1352	.	.	.	O

O	1353	1359	Twenty	Twenty	CD	B-NP
O	1359	1360	-	-	HYPH	I-NP
O	1360	1363	one	one	CD	I-NP
O	1364	1371	percent	percent	NN	I-NP
O	1372	1374	of	of	IN	B-PP
O	1375	1385	clinically	clinically	RB	B-NP
O	1386	1396	unaffected	unaffected	JJ	I-NP
O	1397	1403	family	family	NN	I-NP
O	1404	1411	members	member	NNS	I-NP
O	1412	1415	had	have	VBD	B-VP
O	1416	1424	elevated	elevate	VBN	I-VP
O	1425	1431	levels	level	NNS	B-NP
O	1432	1434	of	of	IN	B-PP
O	1435	1439	bFGF	bFGF	NN	B-NP
O	1439	1440	,	,	,	O
O	1441	1444	and	and	CC	O
O	1445	1447	13	13	CD	B-NP
O	1447	1448	%	%	NN	I-NP
O	1449	1451	of	of	IN	B-PP
O	1452	1460	patients	patient	NNS	B-NP
O	1461	1465	with	with	IN	B-PP
O	1466	1469	EBS	EBS	NN	B-NP
O	1470	1473	had	have	VBD	B-VP
O	1474	1482	elevated	elevate	VBN	I-VP
O	1483	1489	levels	level	NNS	B-NP
O	1490	1492	of	of	IN	B-PP
O	1493	1497	bFGF	bFGF	NN	B-NP
O	1497	1498	.	.	.	O

O	1499	1502	The	The	DT	B-NP
O	1503	1512	frequency	frequency	NN	I-NP
O	1513	1515	of	of	IN	B-PP
O	1516	1524	elevated	elevated	JJ	B-NP
O	1525	1529	bFGF	bFGF	NN	I-NP
O	1530	1536	values	value	NNS	I-NP
O	1537	1542	among	among	IN	B-PP
O	1543	1546	all	all	DT	B-NP
O	1547	1553	groups	group	NNS	I-NP
O	1554	1557	was	be	VBD	B-VP
O	1558	1571	statistically	statistically	RB	B-ADJP
O	1572	1583	significant	significant	JJ	I-ADJP
O	1584	1585	(	(	(	O
O	1585	1586	p	p	NN	B-NP
O	1587	1588	=	=	SYM	B-VP
O	1589	1590	0	0	CD	B-NP
O	1590	1591	.	.	SYM	I-NP
O	1591	1594	002	002	CD	I-NP
O	1594	1595	)	)	)	O
O	1595	1596	,	,	,	O
O	1597	1600	and	and	CC	O
O	1601	1604	the	the	DT	B-NP
O	1605	1611	levels	level	NNS	I-NP
O	1612	1614	of	of	IN	B-PP
O	1615	1619	bFGF	bFGF	NN	B-NP
O	1620	1622	in	in	IN	B-PP
O	1623	1627	RDEB	RDEB	NN	B-NP
O	1628	1636	patients	patient	NNS	I-NP
O	1637	1641	were	be	VBD	B-VP
O	1642	1655	significantly	significantly	RB	B-ADJP
O	1656	1664	elevated	elevated	JJ	I-ADJP
O	1665	1673	compared	compare	VBN	B-PP
O	1674	1678	with	with	IN	B-PP
O	1679	1684	those	those	DT	B-NP
O	1685	1687	of	of	IN	B-PP
O	1688	1693	other	other	JJ	B-NP
O	1694	1700	groups	group	NNS	I-NP
O	1701	1702	(	(	(	O
O	1702	1703	p	p	NN	B-NP
O	1705	1709	less	less	JJR	B-NP
O	1710	1714	than	than	IN	I-NP
O	1716	1717	0	0	CD	I-NP
O	1717	1718	.	.	.	I-NP
O	1718	1720	05	05	CD	I-NP
O	1720	1721	)	)	)	O
O	1721	1722	.	.	.	O

O	1723	1734	CONCLUSIONS	CONCLUSIONS	NNS	B-NP
O	1734	1735	:	:	:	O
O	1736	1738	We	We	PRP	B-NP
O	1739	1743	have	have	VBP	B-VP
O	1744	1749	found	find	VBN	I-VP
O	1750	1754	that	that	IN	B-SBAR
O	1755	1763	patients	patient	NNS	B-NP
O	1764	1768	with	with	IN	B-PP
O	1769	1773	RDEB	RDEB	NN	B-NP
O	1774	1778	have	have	VBP	B-VP
O	1779	1787	elevated	elevate	VBN	I-VP
O	1788	1794	levels	level	NNS	B-NP
O	1795	1797	of	of	IN	B-PP
O	1798	1802	bFGF	bFGF	NN	B-NP
O	1802	1803	,	,	,	O
O	1804	1809	which	which	WDT	B-NP
O	1810	1813	may	may	MD	B-VP
O	1814	1824	contribute	contribute	VB	I-VP
O	1825	1827	to	to	TO	B-PP
O	1828	1837	increased	increase	VBN	B-NP
O	1838	1848	fibroblast	fibroblast	NN	I-NP
O	1849	1860	collagenase	collagenase	NN	I-NP
O	1861	1864	and	and	CC	O
O	1865	1868	the	the	DT	B-NP
O	1869	1880	development	development	NN	I-NP
O	1881	1883	of	of	IN	B-PP
B-Cancer	1884	1892	squamous	squamous	JJ	B-NP
I-Cancer	1893	1897	cell	cell	NN	I-NP
I-Cancer	1898	1907	carcinoma	carcinoma	NN	I-NP
O	1907	1908	.	.	.	O

O	1909	1914	These	These	DT	B-NP
O	1915	1922	results	result	NNS	I-NP
O	1923	1930	suggest	suggest	VBP	B-VP
O	1931	1932	a	a	DT	B-NP
O	1933	1938	novel	novel	JJ	I-NP
O	1939	1948	treatment	treatment	NN	I-NP
O	1949	1952	for	for	IN	B-PP
O	1953	1957	RDEB	RDEB	NN	B-NP
O	1957	1958	,	,	,	O
O	1959	1965	namely	namely	RB	B-ADVP
O	1965	1966	,	,	,	O
O	1967	1979	angiogenesis	angiogenesis	NN	B-NP
O	1980	1990	inhibitors	inhibitor	NNS	I-NP
O	1990	1991	,	,	,	O
O	1992	1997	which	which	WDT	B-NP
O	1998	2001	may	may	MD	B-VP
O	2002	2012	antagonize	antagonize	VB	I-VP
O	2013	2016	the	the	DT	B-NP
O	2017	2024	effects	effect	NNS	I-NP
O	2025	2027	of	of	IN	B-PP
O	2028	2032	bFGF	bFGF	NN	B-NP
O	2033	2035	in	in	IN	B-PP
O	2036	2040	this	this	DT	B-NP
O	2041	2049	disorder	disorder	NN	I-NP
O	2049	2050	.	.	.	O

O	2051	2056	There	There	EX	B-NP
O	2057	2060	are	be	VBP	B-VP
O	2061	2070	currently	currently	RB	B-ADVP
O	2071	2073	no	no	DT	B-NP
O	2074	2079	other	other	JJ	I-NP
O	2080	2085	means	mean	NNS	I-NP
O	2086	2088	of	of	IN	B-PP
O	2089	2098	treatment	treatment	NN	B-NP
O	2099	2102	for	for	IN	B-PP
O	2103	2107	this	this	DT	B-NP
O	2108	2116	disorder	disorder	NN	I-NP
O	2116	2117	,	,	,	O
O	2118	2123	which	which	WDT	B-NP
O	2124	2127	has	have	VBZ	B-VP
O	2128	2129	a	a	DT	B-NP
O	2130	2134	high	high	JJ	I-NP
O	2135	2144	morbidity	morbidity	NN	I-NP
O	2145	2148	and	and	CC	I-NP
O	2149	2158	mortality	mortality	NN	I-NP
O	2159	2163	rate	rate	NN	I-NP
O	2163	2164	.	.	.	O

